Kineta, Inc. (NASDAQ:KA) presented new preclinical data on its lead anti-CD27 monoclonal antibody at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The data showed high binding affinity and specificity, strong T cell activation and proliferation, and NK cell activation. The antibody demonstrated in vivo antitumor efficacy as a single agent and in combination with other immunotherapies in multiple solid and hematological mouse tumor models.